General Hematology
Another randomized trial showed convalescent plasma does not benefit patients hospitalized with Covid-19.
1 Dec, 2021 | 09:49h | UTCRelated:
M-A: Convalescent plasma does not reduce mortality in COVID-19.
M-A: Convalescent plasma is safe but does not improve outcomes in the treatment of COVID-19.
RECOVERY Trial: No benefit from convalescent plasma in patients admitted to hospital with COVID-19.
Commentary on Twitter
The TSUNAMI RCT showed that high-titer convalescent plasma (CP) did not reduce the risk of severe respiratory failure or death in hospitalized patients with #COVID19 pneumonia. https://t.co/4q0S2AtfMj
— JAMA Network Open (@JAMANetworkOpen) November 29, 2021
Review: Castleman disease.
26 Nov, 2021 | 09:49h | UTCCastleman disease – Nature Reviews Disease Primers (if the link is paywalled, try this one)
Infographic: Castleman Disease (if the link is paywalled, try this one)
Review: Prevention and management of thrombosis in hospitalized patients with COVID-19 pneumonia.
26 Nov, 2021 | 08:44h | UTC
Guideline for the laboratory diagnosis of iron deficiency in adults (excluding pregnancy) and children.
25 Nov, 2021 | 10:31h | UTC
A prospective cohort study showed a 3.1% risk for recurrent venous thromboembolism at 90 days in patients with subsegmental pulmonary embolism managed without anticoagulation.
24 Nov, 2021 | 08:31h | UTCRisk for Recurrent Venous Thromboembolism in Patients With Subsegmental Pulmonary Embolism Managed Without Anticoagulation: A Multicenter Prospective Cohort Study – Annals of Internal Medicine (link to abstract – $ for full-text)
Commentary on Twitter
First prospective study including patients with isolated SSPE managed without anticoagulation published in @AnnalsofIM. Rate of recurrent VTE is 3.1% . Nice collaboration between @INNOVTE1 and @canvector funded by @HeartandStroke https://t.co/GdcbM1fRp1 @OttMethodsCentr
— Marc Carrier (@MarcCarrier1) November 23, 2021
M-A: Convalescent plasma does not reduce mortality in COVID-19.
21 Nov, 2021 | 23:09h | UTCRelated:
M-A: Convalescent plasma is safe but does not improve outcomes in the treatment of COVID-19.
RECOVERY Trial: No benefit from convalescent plasma in patients admitted to hospital with COVID-19.
M-A: Intravenous iron is associated with increased risk of infection when compared with oral iron or no iron, which must be balanced with the potential benefits of reducing blood transfusion requirements.
19 Nov, 2021 | 10:31h | UTCInvited Commentary: Intravenous Iron and Infection Risk—Still an Unanswered Question – JAMA Network Open
Commentary on Twitter
In this systematic review and meta-analysis, administration of intravenous iron was associated with an increased risk of infection. This risk must be balanced with the potential benefits of treating anemia and reducing blood transfusion requirements. https://t.co/XkNJKCk7M7
— JAMA Network Open (@JAMANetworkOpen) November 12, 2021
Novel gene therapy for hemophilia A leads to sustained expression of clotting factor and reduced bleeding events.
19 Nov, 2021 | 10:25h | UTCOriginal Study: Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A – New England Journal of Medicine
Commentary on Twitter
3.5 years after therapy with factor VIII-containing adeno-associated virus, 16 of 18 men with hemophilia A had enough factor VIII expression that bleeding events were reduced to nearly zero and prophylaxis was discontinued. https://t.co/n3cPyjGDkn pic.twitter.com/vPyz0OmT1S
— NEJM (@NEJM) November 18, 2021
Review: Vaccine-induced immune thrombotic thrombocytopenia.
16 Nov, 2021 | 08:46h | UTCVaccine-induced immune thrombotic thrombocytopenia – The Lancet Haematology
Related:
Vaccine induced immune thrombocytopenia and thrombosis: summary of NICE guidance.
Clinical features of vaccine-induced immune thrombocytopenia and thrombosis.
Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know.
Very rare cases of thrombosis with thrombocytopenia syndrome (TTS) after AstraZeneca vaccine: a global safety database analysis – the estimated rate of TTS after the first dose was 8.1 per million vaccinees; after the second dose, the estimated rate was 2.3 per million vaccinees. (several articles and resources on the subject)
Commentary on Twitter
NEW Viewpoint by @Erik_Klok_MD, @MPaiMD, Menno Huisman & @ProfMakris discussing the epidemiology, pathophysiology, and optimal diagnostic and therapeutic management of vaccine-induced immune thrombotic thrombocytopenia #VITT #COVID19Vaccine https://t.co/FI4NynwzEn pic.twitter.com/9PbjaioA2T
— The Lancet Haematology (@TheLancetHaem) November 12, 2021
#AHA21 – [Not published Yet] A small, randomized study showed stopping ticagrelor only 2-3 days before bypass surgery may be safe.
14 Nov, 2021 | 19:56h | UTCCommentary: RAPID CABG: No Penalty to Early Surgery for ACS After Stopping Ticagrelor – TCTMD
RCT: In patients with chronic kidney diseases and anemia undergoing dialysis, Daprodustat (oral drug) was noninferior to darbepoetin alfa to increase hemoglobin levels and regarding cardiovascular outcomes.
7 Nov, 2021 | 20:18h | UTCDaprodustat for the Treatment of Anemia in Patients Undergoing Dialysis – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
In this phase 3 clinical trial, daprodustat was effective as a treatment for anemia in patients with CKD who were undergoing maintenance hemodialysis or peritoneal dialysis. #KidneyWk https://t.co/ykzSsUlJci pic.twitter.com/0zdlMyOlTf
— NEJM (@NEJM) November 5, 2021
RCT: In patients with chronic kidney diseases and anemia not undergoing dialysis, Daprodustat (oral drug) was noninferior to darbepoetin alfa in increasing hemoglobin levels and regarding cardiovascular outcomes.
7 Nov, 2021 | 20:17h | UTCDaprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
In this trial, daprodustat was as effective as darbepoetin alfa in increasing and maintaining hemoglobin levels in patients with CKD and anemia who were not receiving dialysis. #KidneyWk https://t.co/D2unQFLH6T pic.twitter.com/KqdLfVlkuD
— NEJM (@NEJM) November 5, 2021
ASH Guideline issued a conditional recommendation against routine use of outpatient anticoagulant prophylaxis in patients with COVID-19 being discharged from the hospital.
4 Nov, 2021 | 10:03h | UTC
Anticoagulants and diabetes agents are among the most frequent causes of emergency department visits attributed to medication harms.
27 Oct, 2021 | 01:15h | UTCUS Emergency Department Visits Attributed to Medication Harms, 2017-2019 – JAMA (link to abstract – $ for full-text)
Commentaries:
Number of emergency room visits for medication harms increases with age – MedicalResearch.com
Blood thinners, diabetes meds among top causes of drug-related ER visits – UPI
Guideline: Transfusion strategies in bleeding critically ill adults.
24 Oct, 2021 | 23:47h | UTC
Commentary on Twitter
Transfusion strategies in bleeding critically ill adults current evidence/research areas from @ESICM clinical practice guideline
?massive bleedings
?non‑massive bleedings
?tranexamic acid in traumatic/non‑traumatic hemorrhages
Open #FOAMcc on @yourICM
?️https://t.co/LtEzrLcaM5 pic.twitter.com/Po7eFYpdeW— Intens Care Med (@yourICM) October 22, 2021
NCCN Guideline: Cancer-Associated Venous Thromboembolic Disease.
21 Oct, 2021 | 10:06h | UTCRelated:
ASH 2021 guidelines for prevention and treatment of venous thromboembolism in patients with cancer
Review: venous and arterial thromboembolism in patients with cancer.
WHO Policy Brief: The urgent need to implement patient blood management.
20 Oct, 2021 | 10:15h | UTCThe urgent need to implement patient blood management: policy brief – World Health Organization
Another observational study suggests Rivaroxaban is associated with higher rates of gastrointestinal bleeding than other direct oral anticoagulants.
19 Oct, 2021 | 09:47h | UTCRivaroxaban Is Associated with Higher Rates of Gastrointestinal Bleeding Than Other Direct Oral Anticoagulants: A Nationwide Propensity Score–Weighted Study – Annals of Internal Medicine (link to abstract – $ for full-text)
Commentary: Rivaroxaban Again Linked to More Bleeding vs Other DOACs – TCTMD
Commentary on Twitter
A new study from @uni_iceland and @Landspitali finds that #Rivaroxaban is associated with a higher risk of GI bleeding compared to other direct oral anticoagulants. https://t.co/2J451CN5dD #afib #bleedingrisk #DOAC pic.twitter.com/Q6VSv5Taqg
— Annals of Int Med (@AnnalsofIM) October 13, 2021
Guideline: Management of anticoagulants and antiplatelet agents in cutaneous surgery.
19 Oct, 2021 | 09:50h | UTC
RCT supports the use of therapeutic heparin in moderately ill patients admitted to the hospital with Covid-19.
17 Oct, 2021 | 21:35h | UTCRelated studies (some conflicting results)
Commentary on Twitter
What are the effects of therapeutic heparin compared with prophylactic heparin among moderately ill patients with covid-19 admitted to hospital? #BMJResearch by @sholzberg and colleagues.
Includes a #VisualAbstract summarising the study #BMJInfographichttps://t.co/82VisuBKSU pic.twitter.com/b06TdIJvLX
— The BMJ (@bmj_latest) October 15, 2021
Guidelines for anesthesiologists on patient blood management in cardiac surgery.
17 Oct, 2021 | 21:22h | UTC
Commentary on Twitter
Please check out editorial on patient #blood management in #cardiacsurgery, a collaboration between Society of Thoracic Surgeons, Society of Cardiovascular Anestheisologists and SABM, AmSECT. https://t.co/HHA8SjxNot pic.twitter.com/DAj2TrGYC3
— Jiapeng Huang (@jiapenghuang) September 24, 2021
ASH 2021 guidelines for stem cell transplantation in patients with sickle cell disease.
14 Oct, 2021 | 09:53h | UTCNews release: ASH Releases New Clinical Practice Guidelines on Stem Cell Transplantation in Sickle Cell Disease
Commentary: ASH Issues Guideline on the Use of HSCT for Sickle Cell Disease – HealthDay
Systematic Review: Direct oral anticoagulants (DOACs) may be beneficial for people being treated for cancer who have no therapeutic or prophylactic indication for anticoagulation.
14 Oct, 2021 | 09:44h | UTC
Anemia prevalence in women of reproductive age in low- and middle-income countries between 2000 and 2018.
13 Oct, 2021 | 01:21h | UTCInvited commentary: Anemia in women — an intractable problem that requires innovative solutions – Nature Medicine
RCT: No benefit from antithrombotic therapy (aspirin or apixaban) in outpatients with clinically stable symptomatic COVID-19.
12 Oct, 2021 | 00:28h | UTC
Commentary on Twitter
Data do not support the use of aspirin or apixaban in the outpatient setting to reduce the major adverse cardiovascular or pulmonary consequences associated with symptomatic but clinically stable #SARSCoV2 infection https://t.co/SH6OefXOCj #COVID19
— JAMA (@JAMA_current) October 11, 2021